Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil

Phase 3

Not yet recruiting

• Conditions: Allergic Rhinitis
• Interventions: Drug: Administration of Comparator; Drug: Administration of investigation of Eurofarma drug

• Registration Number: NCT05637710
• Lead Sponsor: Eurofarma Laboratorios S.A.

Brief Summary

AR is the most common respiratory disease worldwide and is clinically defined by the presence of nasal symptoms induced by exposure to allergens, particularly nasal obstruction and pruritus, runny nose and sneezing. The treatment purpose is to prevent or alleviate symptoms as safely and effectively as possible. Above all, it is recommended that patients avoid contact with allergens to which they are sensitive. However, this is often not enough, and pharmacological interventions are often required.

H1 antihistamines (anti-H1) are considered first-line drugs in the treatment of AR1. These drugs effectively relieve symptoms of the immediate phase of AR, such as nasal pruritus, sneezing, runny nose and associated eye symptoms, and partially the nasal blockage characteristic of the late phase of the disease. Due to their excellent safety profile and therapeutic advantages in the treatment of AR, second-generation anti-H1 drugs, such as levocetirizine, should always be prioritized over older compounds in all age groups1.

The combined administration of an antihistamine and an oral decongestant was shown to b more effective than the administration of an antihistamine alone for the relief of AR-associated nasal obstruction1.

Levocetirizine is an active pharmaceutical ingredient (API) registered in the country as a monodrug for oral administration at a dose of 5mg. Pseudoephedrine is not marketed as a monodrug for oral use in our area, but it is registered in FDC with antihistamines, which is why there is no comparator arm treating with pseudoephedrine only. These products are widely used and their efficacy and safety are well known in daily clinical practice in the proposed indication.

Once the absence of a pharmacokinetic interaction between levocetirizine and pseudoephedrine has been confirmed in relative bioavailability studies (RBA), this phase 3 study will be conducted in order to demonstrate the superiority of FDC levocetirizine 5mg / pseudoephedrine 240mg over levocetirizine 5mg administered alone in the symptomatic treatment of AR, particularly with regard to nasal obstruction. The registration seeks to provide a new effective and safe therapeutic option to address these cases.

Detailed Description

The investigational drug consists of a fixed-dose combination (FDC) that contains levocetirizine, a second-generation anti-H1 antihistamine agent, and pseudoephedrine, an oral decongestant, in doses of 5mg and 240mg, respectively, in the dosage form of film-coated tablets. This product is an unprecedented FDC in the country that is indicated for the symptomatic treatment of allergic rhinitis (AR) in patients aged ≥ 12 years.

A multicenter, randomized, parallel-group, double-blind, double-dummy, superiority, active-controlled clinical trial.

Adolescents and adults (aged ≥ 12 years) of both sexes with intermittent or persistent AR will be randomized in a 1:1 ratio to receive the investigational drug (FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratórios S.A.) or levocetirizine 5mg (Zina®), once daily (morning), for seven (07) days.

The severity of nasal allergy symptoms in the last 24 hours (nasal obstruction, runny nose, sneezing and nasal pruritus) will be evaluated through the application of the assessment questionnaire for nasal symptoms in the last 24 hours before, during and at the end of treatment. The severity of the nasal obstruction at that timepoint will also be evaluated immediately before and one (01) hour after the administration of the first dose of the study treatment, carried out at the research site (also in the morning). Participants will be monitored for an additional seven (07) days for safety assessment.

Study Timeline

• Study First Submitted: 2022-11-22
• Study First Submitted QC: 2022-12-01
• Study First Posted: 2022-12-05
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-16
• Last Update Posted: 2024-05-17
• Study Start: 2025-05-30
• Primary Completion: 2026-04-30
• Study Completion: 2026-08-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 754

Inclusion Criteria

Patients of both sexes who meet all of the following criteria will be enrolled in the study:

1. Signature of the Informed Consent Form (ICF) for those over 18 years of age and, when applicable, signature of the Informed Assent Form (IAF) by the participant under 18 years of age and the ICF by the legal representative before any study procedure.
2. Age ≥ 12 years and ≤ 65 years and weight ≥ 40 kg.
3. Clinical diagnosis of intermittent or persistent allergic rhinitis according to the definition of the Allergic Rhinitis and its Impact on Asthma2 (ARIA) group (Attachment 1) for at least two (02) years.

Exclusion Criteria

Patients who meet at least one of the following criteria will be excluded from the study:

1. Concomitant presence of other types of rhinitis (such as infectious rhinitis, drug rhinitis, rhinitis in the elderly, hormonal rhinitis, non-allergic occupational rhinitis) when known.
2. Presence of significant septal deviation, compatible with impaired nasal ventilatory function, at the discretion of the investigator.
3. Presence of nasal polyposis on anterior rhinoscopy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 2	Administration of Comparator	Comparator group: Levocetirizine 5mg (Zina® - comparator drug)
Group 1	Administration of investigation of Eurofarma drug	Investigational group: FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratórios S.A.

Primary Outcome Measures

Name	Time	Method
Primary efficacy endpoint	In the last 24 hours determined seven (07) days after the ingestion of the first dose	Absolute variation of the nasal obstruction score in the last 24 hours (VEON24D7) determined seven (07) days after the ingestion of the first dose of the IP in relation to the baseline score (VEON24D7 = EON24D7 - EON24D0), and the nasal obstruction scores correspond to the severity of this symptom in the last 24 hours (question 1 of the assessment questionnaire for nasal symptoms in the last 24 hours) and are evaluated on a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate and 3 = severe).

Secondary Outcome Measures

Name	Time	Method
Secondary efficacy endpoints	Absolute variation of the nasal obstruction score at that timepoint determined one (01) hour after the ingestion of the first dose	• Absolute variation of the nasal obstruction score at that timepoint (VEONm1h) determined one (01) hour after the ingestion of the first dose of the IP in relation to the baseline score (VEONm1h = NEOm1h - NEOm0h), and the nasal obstruction scores at that timepoint correspond to the severity of this symptom at the time of evaluation and are evaluated on a 4-point categorical scale (0 = absent, 1 = mild, 2 = moderate and 3 = severe).

Trial Locations

Locations (1)

Eurofarma Laboratorios S.A; 🇧🇷 São Paulo, Brazil